1. Home
  2. RBBN vs EDIT Comparison

RBBN vs EDIT Comparison

Compare RBBN & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ribbon Communications Inc.

RBBN

Ribbon Communications Inc.

HOLD

Current Price

$3.06

Market Cap

493.4M

Sector

Technology

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$3.02

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBBN
EDIT
Founded
1997
2013
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.4M
432.8M
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
RBBN
EDIT
Price
$3.06
$3.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$4.67
$5.30
AVG Volume (30 Days)
1.1M
3.0M
Earning Date
04-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
170.97
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
$1.97
N/A
Revenue Next Year
$6.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$1.83
$1.66
52 Week High
$4.29
$4.54

Technical Indicators

Market Signals
Indicator
RBBN
EDIT
Relative Strength Index (RSI) 57.12 50.81
Support Level $2.72 $2.42
Resistance Level $3.13 $3.27
Average True Range (ATR) 0.19 0.34
MACD 0.03 -0.00
Stochastic Oscillator 59.69 39.22

Price Performance

Historical Comparison
RBBN
EDIT

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: